A psychodermatological review published in Cureus examines how digital skincare marketing influences self-experimentation and treatment adherence in acne vulgaris, framing the findings as a challenge clinicians can no longer leave at the exam-room door.

The review centers on a straightforward clinical tension. Acne vulgaris remains one of the most common dermatologic conditions dermatologists manage, and effective first-line therapies — topical retinoids, benzoyl peroxide, antibiotics, and, for appropriate candidates, systemic agents — depend on sustained, months-long adherence to work. Yet patients increasingly arrive at their appointments having already trialed products they discovered online, often abandoning prescribed regimens before those regimens have had a chance to demonstrate efficacy.

Digital skincare marketing, the review argues, sits at the center of that behavior. Social media platforms, influencer content, and direct-to-consumer brand campaigns now function as a parallel information channel that competes with clinical guidance. Unlike a consultation, this channel runs continuously, is optimized for engagement rather than outcomes, and presents products with claims that patients may not be able to distinguish from evidence-based recommendations. The review treats this not as a marginal annoyance but as a psychodermatological variable — one that shapes beliefs about acne, expectations about treatment timelines, and ultimately the willingness to stick with a prescribed plan.

Self-experimentation is the behavioral consequence the authors highlight. Patients test products they see marketed online, frequently rotating through them at intervals too short to assess any single intervention. That pattern mirrors a known adherence problem in acne care: visible improvement takes weeks, and abandonment in the interim is common. When each abandoned product is replaced by a newly marketed one, the cycle reinforces itself. The review's psychodermatological framing connects this behavior to the emotional burden of acne, which includes effects on self-image and quality of life that make patients especially receptive to promises of rapid results.

The clinical stakes are concrete. Interrupted or repeatedly restarted regimens undermine therapeutic outcomes and complicate the dermatologist's assessment of what, if anything, has actually been tried at adequate duration and dose. The review positions treatment adherence as the measurable endpoint at risk — the factor that determines whether an evidence-based prescription behaves like one in practice.

For clinicians, the review's perspective is practical rather than alarmist. Patients will continue to encounter digital skincare marketing; the question is how the therapeutic relationship absorbs it. Understanding what patients have already self-trialed, why they abandoned it, and where their expectations were formed gives dermatologists a way to reframe the conversation around realistic treatment timelines and the rationale for persisting through the weeks before improvement becomes visible.

The review suggests that acknowledging the digital information environment, rather than dismissing it, belongs in the standard acne consultation. As marketing channels grow more sophisticated and more personalized, the gap between engagement-driven product claims and regimen-based clinical care is likely to widen — and dermatologists who can speak to both will be better positioned to keep patients on therapy long enough for it to work.